Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganetespib - Aldeyra Therapeutics

Drug Profile

Ganetespib - Aldeyra Therapeutics

Alternative Names: ADX 1612; SARC 023; STA-9090

Latest Information Update: 29 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Aldeyra Therapeutics; Cancer Research UK; Cardiff University; Emory University; Innsbruck Medical University; Madrigal Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; Synta Pharmaceuticals
  • Class Antineoplastics; Antivirals; Eye disorder therapies; Indoles; Resorcinols; Small molecules; Triazoles
  • Mechanism of Action HSP90 heat-shock protein inhibitors; Nucleic acid inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Malignant-mesothelioma; Ovarian cancer
  • Suspended Lymphoproliferative disorders
  • Discontinued Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; COVID 2019 infections; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Rectal cancer; Sarcoma; Small cell lung cancer; Uveal melanoma

Most Recent Events

  • 01 Sep 2023 Katholieke Universiteit Leuven completes the phase II trial for Ovarian cancer (Combination therapy, Second line therapy or greater) in Belgium, France, Italy, Germany, Austria (NCT03783949)
  • 29 Sep 2022 Discontinued - Phase-II for COVID-2019 infections (IV)
  • 29 Sep 2022 Discontinued - Phase-II for Ovarian cancer (Combination therapy, Second-line therapy or greater) in Italy (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top